tbuckley/cabot-search huggingface dataset:
ALCOHOL AND SYPHILIS AS CAUSES OF MENTAL DISEASE
Journal: JAMA (1921)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Update on overall survival in COLUMBUS: A randomized phase III trial of encorafenib (ENCO) plus binimetinib (BINI) versus vemurafenib (VEM) or ENCO in patients with <i>BRAF</i> V600–mutant melanoma.
Authors: Gabriella Liszkay, Helen Gogas, Mario Mandalà, ANA Maria Arance Fernandez, Claus Garbe, Dirk Schadendorf, Reinhard Dummer, Paolo Antonio Ascierto, Caroline Robert, Michael D Pickard, Victor Sandor, Ashwin Gollerkeri, Keith Flaherty
Journal: Journal of Clinical Oncology (2019)

9512 Background: BRAF/MEK-inhibitor combinations have a central role in the treatment of BRAF V600–mutant melanoma based on demonstrated benefits on progression-free survival (PFS) and overall survival (OS). Because of these meaningful improvements in outcome, mature landmark analyses of PFS and OS, as well as analyses of some prognostic subgroups, require long-term follow-up. Here we report an updated analysis of OS and other endpoints from the COLUMBUS trial. Methods: In Part 1 of COLUMBUS, 577 patients with advanced/metastatic BRAF V600‒mutant melanoma, untreated or progressed after first-line immunotherapy, were randomized 1:1:1 to ENCO 450 mg QD + BINI 45 mg BID (COMBO450) vs VEM 960 mg BID (VEM) or ENCO 300 mg QD (ENCO300). An updated analysis including PFS, OS, objective response rate (ORR), safety and tolerability, and analyses of results by prognostic subgroups including elevated lactate dehydrogenase (LDH) and degree of organ involvement was conducted after an additional 12 months’ follow-up. Results: At data cutoff, there were 116, 113, and 138 deaths in the COMBO450, ENCO300, and VEM treatment arms, respectively. Across arms, median follow-up for OS was 48.6 months (mo), with median OS of 33.6 mo (95% CI, 24.4–39.2) for COMBO450, 23.5 mo (95% CI, 19.6–33.6) for ENCO300, and 16.9 mo (95% CI, 14.0–24.5) for VEM. Compared to VEM, COMBO450 decreased the risk of death by 39% (HR, 0.61 [95% CI, 0.48–0.79). Updated median PFS was COMBO450, 14.9 mo (95% CI, 11.0–20.2), ENCO300, 9.6 mo (95% CI, 7.4–14.8), and VEM, 7.3 mo (95% CI, 5.6–8.2). PFS was longer for COMBO450 vs VEM (HR, 0.52 [95% CI, 0.40–0.67). Landmark OS and PFS results, as well as subgroup analyses and updated safety and tolerability, will be presented. Conclusions: Updated PFS and OS results for COMBO 450 from the COLUMBUS trial continue to represent new benchmarks for combined BRAF/MEK-inhibitor combinations for treatment of BRAF V600‒mutated melanoma. Clinical trial information: NCT01909453.
Naturwissenschaftliche Reihe.
Journal: JAMA (1928)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Fifth Annual Colorado Pain Symposium: The Surgical Management of Pain
Journal: Endocrine Reviews (1982)

Journal Article Fifth Annual Colorado Pain Symposium: The Surgical Management of Pain Get access Endocrine Reviews, Volume 3, Issue 3, 1 July 1982, Page 244, https://doi.org/10.1210/edrv-3-3-244 Published: 01 July 1982
Barrett’s Esophagus
Authors: A. Rastogi, P. Sharma
Journal: Endoscopy (2005)

Barrett’s esophagus is the displacement of the squamocolumnar junction proximal to the gastroesophageal junction, with the presence of intestinal metaplasia [1]. The clinical importance of Barrett’s esophagus lies in that it is a risk factor for the development of esophageal adenocarcinoma. The past three decades have seen a significant increase in the incidence of adenocarcinoma of the esophagus and the esophagogastric junction in western countries [2] [3] [4]. Esophageal adenocarcinoma now accounts for more than 50 % of all esophageal cancers in the United States and western Europe [3] [5]. The mortality rate of this malignancy is high and the mean 5-year survival rate in patients with advanced disease is less than 20 % [6] [7]. Over the last several years, Barrett’s esophagus has been the focus of intense clinical research with attempts to unravel various controversial aspects of this lesion such as etiopathogenesis, utility of screening and surveillance, surveillance intervals, treatment of dysplasia, etc. We will summarize here some of the important abstracts relating to different clinical aspects of Barrett’s esophagus that were presented at the 2005 Digestive Diseases Week in Chicago, USA.
THE FAT-SOLUBLE VITAMINS
Journal: JAMA (1924)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
From the National Institutes of Health
Authors: James B. Wyngaarden
Journal: JAMA (1987)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Serum ?-glutamyl-transpeptidase isoenzymes in cirrhosis and hepatocellular carcinoma Clinical Medica I and *Laboratorio Analisis Cliniche; Universit� di Pisa, Pisa, Italy
Journal: Hepatology (1995)

Chronic graft-vs-host disease (GVHD) has certain similarities with autoimmune diseases and is associated with the development of various autoantibodies in some patients. In this study, we analyzed the occurrence of autoantibodies in 63 patients surviving longer than 3 months after an allogeneic haematopoietic stem cell transplantation (HSCT), with the aim of detecting a possible association between occurrence of autoantibodies and development of chronic GVHD and immune recovery after HSCT.The patients were screened every 3 months for the occurrence of the following autoantibodies: anti-nuclear (ANA), anti-mitochondrial (AMA), anti–smooth muscle (ASMA), anti-cardiolipin (ACLA), anti-liver-kidney microsomal (LKM), anti-DNA, anti-neutrophil cytoplasmatic (ANCA), and anti-thyroid antibodies. Peripheral blood immunophenotyping with anti-CD3, CD4, CD8, CD19, CD20, CD16, and CD56 antibodies was evaluated at the same intervals.Autoantibodies were not found in 18 patients (29%), at least in one screening in 29 patients (46%), and in all screenings in 16 patients (25%). ANA were found in 41 patients (65%), AMA in 4 (6%), ASMA in 4 (6%), ANCA in 7 (11%), ACLA in 1 (2%), anti-thyroid antibodies in 3 (5%), and anti-DNA in 2 (3%). More than one antibody occurred in 16/63 (25%) positive patients. ANA was significantly more frequent in patients with chronic GVHD and, among these, in those with the extensive form. The nucleolar pattern of immunofluorescence of ANA but not its titer was correlated with the extension of chronic GVHD. Patients who developed autoantibodies had higher CD20+ cell blood counts than negative patients in the third month (p = 0.006), ninth month (p = 0.061), and twelfth month (p = 0.043).We conclude that patients with chronic GVHD, particularly those with an extensive involvement, were likely to develop autoantibodies and have a faster B-cell recovery, suggesting a role of B cells in the pathogenesis of chronic GVHD.
This Week in &lt;EMPH&gt;JAMA&lt;/EMPH&gt;
Journal: JAMA (2004)

Chelsea S. Kidwell, MD; Julio A. Chalela, MD; Jeffrey L. Saver, MD; Sidney Starkman, MD; Michael D. Hill, MD; Andrew M. Demchuk, MD; John A. Butman, MD, PhD; Nicholas Patronas, MD; Jeffry R. Alger, PhD; Lawrence L. Latour, PhD; Marie L. Luby, MEng, MS; Alison E. Baird, FRACP, PhD; Megan C. Leary, MD; Margaret Tremwel, MD, PhD; Bruce Ovbiagele, MD; Andre Fredieu, MD; Shuichi Suzuki, MD, PhD; J. Pablo Villablanca, MD; Stephen Davis, MD; Billy Dunn, MD; Jason W. Todd, MD; Mustapha A. Ezzeddine, MD; Joseph Haymore, MS, ACNP; John K. Lynch, DO, MPH; Lisa Davis, MSN, RN; Steven Warach, MD, PhD
Meta-analysis of endoscopic ligation (EL) and endoscopic sclerotherapy (ES) in the prevention of gastrointestinal rebleeding in patients with cirrhosis . Service d'H�pato-Gastroent�rologie, H�pital Piti�-Salp�tri�re, 75651 Paris. *INSERM U-24, H�pital Beaujon. 92118 Clichy, France
Journal: Hepatology (1995)
Outcome of pregnancy after induced ovulation. Follow-up of pregnancies and children born after clomiphene therapy
Authors: M. Hack
Journal: JAMA (1972)

Eighty-six women reached at least 20 weeks' pregnancy in 96 instances, after ovulation induced by clomiphene citrate. Although 37 of the women had 44 previous pregnancies, there had been a high pregnancy wastage (70.5%) producing only 13 live infants prior to the successful clomiphene therapy. After clomiphene therapy, pregnancies were normal except for a high incidence of toxemia (16.7%) and a possibly increased incidence of prediabetes. The pregnancies resulted in 88 single and 8 twin births. The total fetal and neonatal loss was 6.7%. The loss of single births (3.1%) included two stillbirth infants of prediabetic mothers. The twin loss of 25% was due to prematurity. The incidence of congenital malformations was within normal limits.
Randomized, double-blind, phase III trial to compare the efficacy of ipilimumab (Ipi) versus placebo in asymptomatic or minimally symptomatic patients (pts) with metastatic chemotherapy-naïve castration-resistant prostate cancer (CRPC).
Authors: T. M. Beer, C. Logothetis, P. Sharma, W. R. Gerritsen, R. Ezzeddine, J. P. Fairchild, P. Gagnier, K. M. Chin, J. Cuillerot
Journal: Journal of Clinical Oncology (2011)

TPS182 Background: While docetaxel is standard therapy for metastatic CRPC, its use may be delayed until patients develop symptoms. Thus, patients with asymptomatic or minimally symptomatic metastatic CRPC may derive benefit from a non-chemotherapeutic treatment in this setting. Ipilimumab (ipi), an anti-cytotoxic T lymphocyte antigen-4 (CTLA-4) monoclonal antibody, has demonstrated survival benefit in a phase III trial for advanced melanoma, with side effects that were managed using product-specific treatment guidelines. In addition, ipi has shown promising clinical activity as monotherapy, with no unexpected toxicities, in phase II trials in metastatic CRPC. As such, this global phase III study (~150 sites in 25 countries) is evaluating ipi vs placebo in chemotherapy-naïve pts with asymptomatic or minimally symptomatic CRPC without visceral metastases. Methods: The primary endpoint is OS; secondary endpoints include progression-free survival, time to pain progression, and time to non-hormonal systemic therapy. Pts are randomized at a 2:1 ratio to receive ipi 10 mg/kg every 3 weeks for up to 4 doses or placebo, respectively, as induction therapy. Treatment Stopping Criteria (TSC) have been prospectively defined to enable decision making. After completing induction, pts who have not met TSC will continue to receive maintenance therapy of blinded study drug every 12 weeks until TSC are met, withdrawal of consent, or study closure. Target enrollment is 600 pts. Enrollment has been ongoing since August 2010 (ClinicalTrials.gov identifier: NCT01057810). Inclusion criteria Metastatic CRPC Asymptomatic or minimally symptomatic Progression during prior hormonal therapy Discontinuation of anti-androgens Testosterone < 50 ng/dl ECOG performance status 0-1 Exclusion criteria Liver, lung, or brain metastases Prior immunotherapy or chemotherapy for metastatic CRPC Autoimmune disease HIV, Hep B, or Hep C infection Pelvic targeted RT within 3 months of study
Number 46
Authors: Russell Portenoy
Journal: JAMA (1983)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Esophageal Exfoliative Cytology: A Neglected Procedure
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Obstetrics and Gynecology
Authors: T. Keith Edwards
Journal: JAMA (1982)

How would you like to have 75 authorities at your beck and call? This new edition of<i>Obstetrics and Gynecology</i>can place that number in your library. The contributors summarize and offer their best ideas and opinions on the various aspects of our specialty. Each one sees that specialty from a different vantage point, partly because of background and training and partly because of the assigned topic covered. Dr Danforth is from Chicago and has been joined in the editorial work of this volume by Dr William Dignam of Los Angeles, Dr Charles Hendricks of Chapel Hill, NC, and Dr John Maeck of Burlington, Vt, giving this work the advantage of opinion from a wide geographical area in the United States. The book is divided into eight parts with a varying number of chapters under each section, and I found that the index was sufficiently detailed to enable me to
Glucose suppression of serum growth hormone in the diagnosis of acromegaly
Authors: J. M. Earll
Journal: JAMA (1967)

The range of serum immunoreactive human growth hormone (IRHGH) levels found in normal and acromegalic individuals prevented complete separation of the two groups. A test has been devised whereby IRHGH levels are determined before and one hour after administration of 100 gm of glucose orally. Nonacromegalic individuals suppress IRHGH to minimally detectable levels. Patients with acromegaly show responses ranging from paradoxical elevations and fixed levels to only moderate degrees of suppression, but not to the very low levels of normal individuals.
Highlights
Authors: Howard Bauchner
Journal: JAMA (2015)

Surgical resection is the most important treatment modality for rectal cancer, with surgical integrity of the specimen and tumor pathologic staging important prognostic factors.In a multicenter, noninferiority, randomized trial that enrolled 486 patients who had completed neoadjuvant therapy for locally advanced rectal cancer (stage II and stage III), Fleshman and colleagues assessed the effi cacy of laparoscopic-assisted resection vs open resection.The authors report that laparoscopic resection failed to meet the study criterion for pathologic noninferiority-a composite outcome of total mesorectal excision completeness and negative distal and circumferential radial margin results.In an Editorial, Strong and Soper discuss minimally invasive operations for colorectal disorders.
Errors in Panels B and C in Figure 1
Journal: JAMA Network Open (2020)

Hana D’Souza, PhD; Luke Mason, PhD; Kin Y. Mok, PhD; Carla M. Startin, PhD; Sarah Hamburg, PhD; Rosalyn Hithersay, PhD; R. Asaad Baksh, PhD; John Hardy, PhD; Andre Strydom, MD; Michael S. C. Thomas, PhD; London Down Syndrome (LonDownS) Consortium
THE INFLUENCE OF BACTERIA IN THROMBOSIS.
Journal: JAMA (1901)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Announcement Spotlight Issue on the TGFbeta Superfamily in Cardiovascular Biology
Journal: Cardiovascular Research (2006)

A Spotlight Issue on the transforming growth factor ␤ (TGF␤) superfamily, comprising TGFβ itself, bone morphogenetic protein (BMP), activin, and other peptide cytokines, is scheduled to appear in May, 2007, that will address the critical role of these growth factors in cardiovascular development and physiology as well as in a variety of cardiovascular disease states, including atherosclerosis, ischemic heart disease, and heart failure.In addition, there will be detailed information on TGFβ receptors, modes of activation, and subsequent mechanisms of intracellular signaling.Putative targets of pharmacological intervention will also be covered.Preliminary topics of invited review articles related to the cardiovascular biology of the TGFβ superfamily include:
The Impact of Mandatory Continuing Medical Education
Authors: Jeoffrey K. Stross, William R. Harlan
Journal: JAMA (1978)

MANY states are either moving toward or have adopted legislation that mandates physician participation in continuing medical education (CME). To date, 13 states have CME requirements in effect, another ten states have passed enabling legislation that has not been implemented, and the others have not taken formal action. In June 1975, the governor of Michigan signed into law Public Act 112, which mandates participation in CME as a prerequisite for annual reregistration of the license to practice medicine. Each physician must show evidence of participation in 50 hours of CME activities, approved by the Board of Medical Examiners, in the calendar year before application for reregistration. This law appears to result from a concept, held by many legislators, that CME provides a handle on medical practice and that manipulation of that handle will result in direct and desirable effects on medical practice. Participation in CME is perceived as a means